Key Events This Week
4 May: Week opens at Rs.212.25
5 May: Technical momentum shifts amid mixed indicator signals
7 May: Mojo Grade upgraded from Strong Sell to Sell
8 May: Stock closes at Rs.217.90, up 2.13% on the day

Jagsonpal Pharmaceuticals Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges
2026-05-08 08:05:00Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s quality, valuation, financial trend, and technical parameters have been reassessed, reflecting a nuanced outlook for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news article
Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-05-08 08:00:16Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 1.84%, the stock’s technical indicators present a complex picture, with mixed signals across weekly and monthly timeframes, reflecting uncertainty in near-term price direction.
Read full news article
Jagsonpal Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-05-05 08:00:16Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.93%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, reflecting cautious investor sentiment in the Pharmaceuticals & Biotechnology sector.
Read full news articleJagsonpal Pharmaceuticals Gains 5.44%: Mixed Technical Signals Shape Weekly Momentum
2026-05-03 16:00:04
Key Events This Week
27 Apr: Stock opens strong at Rs.203.95 (+2.26%) amid positive market sentiment
28 Apr: Q4 FY26 results reveal profit surge; technical momentum shifts amid mixed indicators
29 Apr: Technical momentum moves to sideways trend with continued gains (+1.19%)
30 Apr: Week closes at Rs.210.30, up 5.44% for the week, outperforming Sensex

Jagsonpal Pharmaceuticals Ltd is Rated Strong Sell
2026-05-03 10:10:13Jagsonpal Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 03 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Jagsonpal Pharmaceuticals Ltd: Technical Momentum Shifts Amid Mixed Indicator Signals
2026-04-29 08:00:12Jagsonpal Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a complex technical profile with a shift from mildly bearish to sideways momentum. Despite a modest day gain of 1.20%, the stock’s technical indicators present a nuanced picture, reflecting both bullish and bearish signals across weekly and monthly timeframes.
Read full news articleAre Jagsonpal Pharmaceuticals Ltd latest results good or bad?
2026-04-28 19:13:41Jagsonpal Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture. The company reported a net profit of ₹8.76 crores, reflecting a year-on-year growth of 33.13%. However, this represents a sequential decline of 20.00% compared to the previous quarter. Similarly, revenue for the quarter was ₹64.20 crores, which is a 9.63% increase year-on-year but shows a significant sequential contraction of 11.99% from ₹72.95 crores in Q3 FY26. The operating margin, excluding other income, was recorded at 17.38%, which is an improvement of 248 basis points year-on-year but a notable decrease of 494 basis points from the previous quarter's margin of 22.32%. This decline in margins raises concerns about the company's operational efficiency and cost management in the face of revenue pressures. Overall, while Jagsonpal Pharmaceuticals has demonstrated resilience in year-on-year comparisons, the se...
Read full news article






